The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...
Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, ...
U.S. regulators have accepted a new submission for Vyglxia, offering the chance at a turnaround for another rare disease ...
Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug ...
Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also ...
In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...
Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s ...
The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a ...
Roche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a ...
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an ...
City Therapeutics, a buzzy biotechnology startup working on new types of RNA interference therapies, secured $200 million in ...
Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results